Epidemiology of adverse drug reactions in the elderly by drug class

被引:70
作者
Beyth, RJ
Shorr, RI
机构
[1] Case Western Reserve Univ, Sch Med, Div Gen Internal Med & Healthcare Res, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland, Cleveland Vet Affairs Med Ctr, Div Gen Internal Med & Healthcare Res, Cleveland, OH 44106 USA
[3] Univ Tennessee, Coll Med, Dept Preventat Med, Memphis, TN USA
[4] Methodist Hosp Memphis, Memphis, TN USA
关键词
D O I
10.2165/00002512-199914030-00005
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
As the growth of the elderly population continues, the burden on the health care system and society will also increase. Since chronic diseases such as hypertension, coronary artery disease, arthritis, stroke, cancer and diabetes mellitus are more prevalent with age, the number of people with multiple chronic diseases will also increase. These patients are likely to be treated for some or all of their conditions with drug therapies. When used appropriately, drugs may be the single most important intervention in the care of an older patient, but when used inappropriately they no longer provide therapeutic benefit, and they may even endanger the health of an older patient by causing an adverse drug reaction (ADR), Factors believed to be responsible for increased adverse reactions in elderly patients are polypharmacy (including prescription and over-the-counter medications), increased drug-drug interaction, pharmacokinetic changes, pharmacodynamic changes, the pathology of aging and compliance. The exact role that age plays in ADRs is not clear. This is in part because few older patients are included in the large randomised trials, and so much of the information used to ascertain the age-associated risks of drugs comes from observational studies, Although the interactions of aging, concurrent comorbidities and polypharmacy are known, older patients do appear to be at increased risk. Improvements in the management of drug therapies of older patients can lead to improvements in their overall health, functioning and safety, as well as providing potential benefits to society by ameliorating some of the burden of their health care.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 76 条
  • [1] *AM DIAB ASS, 1997, DIABETES CARE S1, V20, pS5
  • [2] [Anonymous], ADV DATA VITAL HLTH
  • [3] Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation
    Antani, MR
    Beyth, RJ
    Covinsky, KE
    Anderson, PA
    Miller, DG
    Cebul, RD
    Quinn, LM
    Landefeld, CS
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (12) : 713 - 720
  • [4] NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND LIFE THREATENING COMPLICATIONS OF PEPTIC-ULCERATION
    ARMSTRONG, CP
    BLOWER, AL
    [J]. GUT, 1987, 28 (05) : 527 - 532
  • [5] AVORN J, 1990, GERIATRIC MED, P68
  • [6] NEW ROLE FOR PHARMACIST IN DETECTION AND EVALUATION OF ADVERSE DRUG REACTIONS
    BERGMAN, HD
    AOKI, VS
    BLACK, HJ
    LEAVERTON, PE
    DICK, RW
    WILSON, WR
    [J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1971, 28 (05): : 343 - +
  • [7] Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?
    Beyth, RJ
    Antani, MR
    Covinsky, KE
    Miller, DG
    Chren, MM
    Quinn, LM
    Landefeld, CS
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (12) : 721 - 728
  • [8] ANTICOAGULANTS IN OLDER PATIENTS - A SAFETY PERSPECTIVE
    BEYTH, RJ
    LANDEFELD, CS
    [J]. DRUGS & AGING, 1995, 6 (01) : 45 - 54
  • [9] BEYTH RJ, 1992, CLIN RES, V40, pA552
  • [10] Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality
    Classen, DC
    Pestotnik, SL
    Evans, RS
    Lloyd, JF
    Burke, JP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04): : 301 - 306